Insight Capital Research & Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Insight Capital Research & Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-24,395	Closed	-$847K	–	120
2015 Q2	$847K	Buy	+24,395	New	+$744K	0.22%	86
2014 Q3	–	Sell	-536,522	Closed	-$8.49M	–	155
2014 Q2	$8.49M	Buy	+536,522	New	+$7.66M	1.94%	7

Other funds holding HZNP

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Insight Capital Research & Management's HZNP Position: Q3 2015 in Review

Insight Capital Research & Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2015, closing a stake of 24,395 shares — an estimated $847K sold.

Insight Capital Research & Management first reported a position in HZNP in Q2 2014 and held it in 2 quarters. The position peaked at $8.49M in Q2 2014. 223 funds tracked by Wall St. Rank hold HZNP as of Q3 2015.

Insight Capital Research & Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2015 after selling out during the quarter.
Insight Capital Research & Management sold 24,395 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2015, an estimated $847K.
Insight Capital Research & Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2014 and held it in 2 quarters.
Insight Capital Research & Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $8.49M in Q2 2014.
223 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2015.

Based on Insight Capital Research & Management's 13F filing for Q3 2015, filed 5 Nov 2015.